Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
|Articles|February 1, 2005
- Volume 0 0
Warning Added to ADHD Drug
Advertisement
Eli Lilly and Co is taking swift actionto notify pharmacists, physicians, andpatients regarding the warning added toits drug Strattera. The drug is indicatedfor the treatment of attentiondeficit/hyperactivity disorder (ADHD)in children, adolescents, and adults. Thewarning indicates that the medicationshould be stopped in patients with jaundiceor laboratory evidence of liverinjury. The revised label discusses 2reported cases of severe liver injury outof >2 million patients who have takenthe medication since its approval. Thepatients who experienced the liver problemshave had normal liver functionsince discontinuing the medication.
Lilly has been notifying physicians,other health care providers, and consumeradvocacy and professionallyfocused associations regarding the labelchange so that they have the tools toprovide important information topatients. Lilly's outreach efforts includea "Dear Healthcare Professional" letter,sales force communication to prescribers,and information on Strattera'sWeb site (www.strattera.com). "Patientsafety is our top priority at Lilly," saidDouglas Kelsey, MD, a pediatrician anda clinical research physician at Eli Lillyand Co, in a press statement.
Articles in this issue
almost 22 years ago
Issues in the Treatment of Patients with Hypothyroidismalmost 22 years ago
Health Organizations Favor Electronic Health Recordsalmost 22 years ago
Therapeutic Management of Bronchitisalmost 22 years ago
Program Advocates for Timely Prescription Refillsalmost 22 years ago
Cardinal Backs RFID Technologyalmost 22 years ago
Agreement Improves Point of Carealmost 22 years ago
Decision Unpopular with Health Care Professionalsalmost 22 years ago
Unemployment Benefits Denied When Pharmacist Quits Work Because of Stressalmost 22 years ago
The Importance of the Order of Drug Administrationalmost 22 years ago
Beware of Erroneous Daily Oral Methotrexate Dosing!Advertisement
Related to this article
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
The Most Accessible Healthcare Professional—But Accessible to Whom?
5